Abstract:
Compounds of formula (I): wherein: R1 represents alkyl, alkenyl, haloalkyl, polyhaloalkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl or heteroarylalkyl, R2 represents a fluorine atom or an alkyl group substituted by one or more fluorine atoms. Medicinal products containing the same which are useful in treating disorders of the melatoninergic system.
Abstract:
A compound selected from those of formula (I): wherein: R1 represents a group R4 or NHR4, wherein R4 is as defined in the description; R2 represents a substituted linear or branched (C1-C6)alkyl group; R3 represents a hydrogen or halogen atom or a linear or branched (C1-C6)alkyl or linear or branched (C2-C6)alkenyl group. Medicinal products containing the same which are useful in the treatment of disorders of the melatoninergic system.
Abstract:
The invention relatests compound of formula (I): wherein: n is 1, 2 or 3, A represents a group X represents N or NR1, R2 represents an alkoxy, cycloalkyloxy or cycloalkylalkyloxy group. and medicinal products containing the same which are useful in treading or in preventing melatoninergic disorder.
Abstract:
The invention relates to a compound selected from those of general formula (I): ##STR1## in which R, R.sub.1, R.sub.2 and R.sub.3 are as defined in the specification, an optical isomer, and an addition salt thereof with a pharmaceutically-acceptable base.Medicinal product which is useful in the treatment of disorders linked to abnormal melatonin activity.
Abstract:
Compounds of general formula (I): ##STR1## in which: R.sub.1 represents a hydrogen atom or a lower alkyl group,R.sub.2 represents a substituted or unsubstituted alkyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted alkenyl group, a substituted or unsubstituted thienyl, furyl, pyrrolyl or pyridinyl group,X represents a hydrogen atom,Y represents a hydroxyl group,or else X and Y together represent an oxygen atom, their enantiomers, diastereoisomers and epimers. Medicaments.
Abstract:
The invention relates to compound of formula (I) wherein: B represents hydrogen, COOR, CONRR′, or (C1-C6)alkyl substituted by COOR, CONRR′, or OR, G1 represents —X′—(CH2)n—X—(CH2)m—X″— chain wherein X, X′, X″, n and m are as defined in the description, Cy represents a grouping of formula (II) or (III): G2 represents alkylene chain as defined in the description, and A represents NRCOR′, NRCSR′, CONRR′, CSNRR′, NRCONR′R″, or NRCSNR′R″. and medicinal products containing the same which are useful in treating or preventing melatoninergic disorders.
Abstract:
The invention relates to compounds of formula (I): A—G1—Cy—G2—Cy—G3—B (I) wherein: A represents NR1C(Q)R2, C(Q)NR2R3 or NR1C(Q)NR2R3, B represents NR1C(Q)R2, C(Q)NR2R3, NR1C(Q)NR2R3, C(Q)OR1, NR1C(Q)OR2 or NR2R3, G1 and G3 represent an optionally substituted alkylene chain, Cy represents a ring structure and G2 represents a chain and medicinal products containing the same which are useful in treating or in preventing melatoninergic disorders.
Abstract:
Compounds of general formula (I): ##STR1## where R, X, A, B and p are defined in the description. Medicinal products useful for treating sleep disorders comprising the same.
Abstract:
Compounds of general formula (I): ##STR1## where R, X, A, B and p are defined in the description. Medicinal products useful for treating sleep disorders comprising the same.
Abstract:
Compounds of general formula (I): ##STR1## where R, X, A, B and p are defined in the description. Medicinal products useful for treating sleep disorders comprising the same.